New College Lanarkshire is a vibrant and modern college in the heart of Scotland, offering first class learning facilities, support services and employability opportunities. With six campuses in Broadwood, Coatbridge, Cumbernauld, Hamilton, Kirkintilloch and Motherwell, the College offers an extensive range of courses across six faculties.
State-of-the-art facilities put the College at the forefront of the sector for many industries, and commitment to students, stakeholders and the local community has been widely commended. The College has received numerous awards and accolades for its exceptional students, including winning the title of ‘Best in UK’ at WorldSkills UK.
With a strong focus on employability, New College Lanarkshire boasts strong business and industry links, providing opportunities for students to gain hands-on, practical experience in the workplace, while giving local businesses the chance to shape courses.
Part-time or full-time, evening courses or taking up a new hobby, New College Lanarkshire has something for everyone.
South Lanarkshire College is a bright, modern and forward thinking college where we put our students and partners at the heart of everything we do. At our state-of-the-art campus in East Kilbride we offer excellent programmes in outstanding facilities, delivered by well qualified, highly trained staff.
We collaborate with employers and local businesses to make sure that we provide relevant, up-to-date courses that are really of benefit to industry and to our students when they go out into the world of work. We have a fantastic portfolio of courses across a variety of different areas which can be studied on a full time, part time, day release and evening basis so there’s something to suit everyone. We’re also really experienced in designing specialist courses for our partners; we know that one size doesn’t fit all, so we’re delighted to work with you to design a course that really suits you.
We really believe that now is your time to be successful and we’re looking forward to working with you to help you achieve your goals.
Albert Bartlett is a progressive family brand, established in 1948 and dedicated to providing tasty, wholesome food for proper meals. The company is family-owned and proudly run from its base in Airdrie. It is fiercely committed to providing a branded range of the best potatoes grown in the most responsible way. Albert Bartlett potatoes are grown across the UK from the far north of Scotland through the country to Cornwall and across to Northern Ireland and the Island of Jersey. Our range includes the versatile Albert Bartlett Rooster and the creamy, buttery Albert Bartlett Elfe potatoes and we have also recently introduced a range of frozen potato dishes, including Rooster Homestyle Chips and Rooster Roast Potatoes.
The company has a growing international presence in France, UAE and North America. For more information about our potatoes, recipes, farmers and our ambassadors Michel Roux Jr, Andrew Fairlie and Sally Bee, please visit www.albertbartlett.co.uk
At Clydesdale Bank – we care about here. We believe that our intimate local knowledge, and strong banking experience, contributes to the prosperity and future growth of the communities we’re part of.
Our bank was founded in Glasgow in 1838, and today we have over 130 retail branches and 12 Business & Private Banking Centres to support our growing customer base in Scotland.
Our work with Lanarkshire Business Excellence Awards will help us strengthen our support to local businesses. We’re delighted to continue to play a role in helping local businesses realise their ambitions.
Construction work is complete on the first project to use Glasgow and Clyde Valley City Deal funding.
MediCity Scotland, a dedicated medical technology incubation facility based at Biocity Scotland Ltd in Newhouse, North Lanarkshire has been created with the support of £1.012million in capital investment from City Deal, with funding from the UK Department of Business Innovation and Skills, matched with contributions from BioCity Scotland Limited.
A total of 11,000 sq ft of office space and incubation workspace has been constructed through the refurbishment of a vacant building at the BioCity campus.
The state-of-the-art MediCity facility is a physical hub for new and existing medical technology and healthcare businesses in Scotland and will be a focus for expertise in the sector.
Over the next five years the facility aims to support up to 50 new medtech businesses and 150 jobs, develop links between the commercial and academic communities and showcase Scotland to inward investment opportunities in this growing field.
Dr Diane Harbison, Managing Director at BioCity Scotland said: “I am really looking forward to the forthcoming launch of MediCity Scotland later this month. MediCity will follow a similar clustering model to the one already successfully in action here at BioCity, bringing together entrepreneurs, clinicians, developers, innovators and investors in a supportive environment which will facilitate and accelerate medtech opportunities.
“One of the benefits of clustering similar businesses together is that it leads to a higher survival rate – for example, businesses at BioCity Nottingham have a 91% survival rate, which is fantastic.”
“As part of our ongoing success in supporting new businesses and creating jobs locally, North Lanarkshire Council is delighted to be contributing to the revenue funding of this exciting venture with funding of £439,000,” said Councillor Jim McCabe, Leader North Lanarkshire Council.
“MediCity will act as a focal point to encourage more medical-related enterprise to North Lanarkshire, and help to build up a centre of excellence.
“This is the first of a number of projects in North Lanarkshire supported by City Deal, which is a unique and exciting opportunity to invest significantly in public infrastructure, delivering real benefits for the economy and jobs now and in the long term.”
The Glasgow and Clyde Valley City Deal is an agreement between the UK Government, the Scottish Government and the eight local authorities across Glasgow and Clyde Valley. It sets out how the region will create economic growth through:
- setting up a £1.13 billion Glasgow and Clyde Valley Infrastructure Fund to improve transport and regenerate/develop sites
- supporting growth in the life sciences sector
- helping small and medium enterprises to grow and develop
- setting up programmes to support unemployed people
- testing new ways of boosting the incomes of people on low wages.
Scottish pharmaceutical company Alfacyte Ltd is set to move to a new home at life sciences incubator BioCity Scotland in November, after recently securing £350k of investment to advance the development of an oral vaccine for the treatment of peanut allergy.
Peanut allergy affects around 2% of the Western population, and is the most common cause of food-induced fatal allergic reactions.
Alfacyte, currently based in Glasgow, was set up by Professor of Immunology William Stimson and Dr Alistair Strachan in 2012 with the aim of developing drug therapies to treat various food allergies. In Summer 2015 it announced that it had raised £350,000 in equity and grant funding from the EOS Technology Investment Syndicate, Scottish Investment Bank and Scottish Enterprise. The investment will directly fund development and production of the proprietary molecule that will form the basis of a peanut allergy vaccine.
When deciding on a new home that would meet the needs of the growing business, the company chose BioCity Scotland because of the quality of the facilities, easily accessible location beside the M8 between Glasgow and Edinburgh, and the knowledge and expertise of the BioCity team.
Gillian Brown, Alfacyte’s Chief Executive said: “Alfacyte is very pleased to be establishing its business at BioCity Scotland. As a very young and very small SME, we feel BioCity offers not just excellent facilities but an opportunity to mix with similar companies and share experiences. BioCity is more than just a location for our business, we can also benefit from the support and knowledge of its team and its network.”
Dr Diane Harbison, Managing Director of BioCity Scotland said: “Alfacyte is a tremendously exciting and innovative young company and I am delighted that they have chosen to come to BioCity Scotland. Food allergies are a very common life-limiting condition, especially in children, and cause hundreds of fatalities every year, so the development of an oral vaccine to treat peanut allergy has the potential to change thousands of lives all over the world. We look forward to supporting the ongoing development of the company here at BioCity Scotland.”
Dr Harbison added: “BioCity Scotland will become Scotland’s fifth Enterprise Area next year, which means that as well as providing our tenant companies with high spec laboratories and office space, access to expertise, finance and a community of like-minded people, we can also offer them business rates relief, faster planning applications and support and assistance in accessing international markets.”